Analytical and Bioanalytical Chemistry

, Volume 403, Issue 1, pp 203–213

Serum metabolomics reveals the deregulation of fatty acids metabolism in hepatocellular carcinoma and chronic liver diseases

  • Lina Zhou
  • Quancai Wang
  • Peiyuan Yin
  • Wenbin Xing
  • Zeming Wu
  • Shili Chen
  • Xin Lu
  • Yong Zhang
  • Xiaohui Lin
  • Guowang Xu
Original Paper

DOI: 10.1007/s00216-012-5782-4

Cite this article as:
Zhou, L., Wang, Q., Yin, P. et al. Anal Bioanal Chem (2012) 403: 203. doi:10.1007/s00216-012-5782-4

Abstract

Patients with chronic liver diseases (CLD) including chronic hepatitis B and hepatic cirrhosis (CIR) are the major high-risk population of hepatocellular carcinoma (HCC). The differential diagnosis between CLD and HCC is a challenge. This work aims to study the related metabolic deregulations in HCC and CLD to promote the discovery of the differential metabolites for distinguishing the different liver diseases. Serum metabolic profiling analysis from patients with CLD and HCC was performed using a liquid chromatography–mass spectrometry system. The acquired large amount of metabolic information was processed with the random forest–recursive feature elimination method to discover important metabolic changes. It was found that long-chain acylcarnitines accumulated, whereas free carnitine, medium and short-chain acylcarnitines decreased with the severity of the non-malignant liver diseases, accompanied with corresponding alterations of enzyme activities. However, the general changing extent was smaller in HCC than in CIR, possibly due to the special energy-consumption mechanism of tumor cells. These observations may help to understand the mechanism of HCC occurrence and progression on the metabolic level and provide information for the identification of early and differential metabolic markers for HCC.

Keywords

Hepatocellular carcinoma Metabolomic profiling Random forest–recursive feature elimination Acylcarnitine Fatty acid oxidation 

Abbreviations

Q-TOF

Quadrupole time-of-flight

AFP

α-fetoprotein

ALT

Alanine transaminase

AST

Aspartate transaminase

CEA

Carcinoma embryonic antigen

CHB

Chronic hepatitis B

CIR

Hepatic cirrhosis

CLD

Chronic liver diseases

CN

Acylcarnitine

CoA

Coenzyme A

CPT 1

Carnitine palmitoyl transferase 1

CPT 2

Carnitine palmitoyl transferase 2

FAO

Fatty acid oxidation

GCA

Glycocholic acid

GCDCA

Chenodeoxycholic acid glycine conjugate

HBsAg

Hepatitis B surface antigen

HBV

Hepatitis B virus

HCC

Hepatocellular carcinoma

IDO

Indoleamine 2,3-dioxygenase

LC-MS

Liquid chromatography–mass spectrometry system

N

Healthy controls

OOB

Out-of-bag

QC

Quality control

RF

Random forest

RFE

Recursive feature elimination

RF-RFE

Random forest–recursive feature elimination

RRLC

Rapid-resolution liquid chromatography

SCD

Stearoyl-CoA desaturase

T2DM

Type 2 diabetes

TCA

Tricarboxylic acid

γ-GT

γ-glutamyl transpeptidase

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • Lina Zhou
    • 1
  • Quancai Wang
    • 2
  • Peiyuan Yin
    • 1
  • Wenbin Xing
    • 3
  • Zeming Wu
    • 1
  • Shili Chen
    • 1
  • Xin Lu
    • 1
  • Yong Zhang
    • 3
  • Xiaohui Lin
    • 2
  • Guowang Xu
    • 1
  1. 1.CAS Key Laboratory of Separation Science for Analytical ChemistryDalian Institute of Chemical Physics, Chinese Academy of SciencesDalianChina
  2. 2.School of Computer Science and TechnologyDalian University of TechnologyDalianChina
  3. 3.The Sixth People’s HospitalDalianChina

Personalised recommendations